SG Americas Securities LLC Buys 30,508 Shares of Nektar Therapeutics (NASDAQ:NKTR)

SG Americas Securities LLC raised its stake in Nektar Therapeutics (NASDAQ:NKTR) by 69.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 74,450 shares of the biopharmaceutical company’s stock after buying an additional 30,508 shares during the period. SG Americas Securities LLC’s holdings in Nektar Therapeutics were worth $1,278,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Vident Investment Advisory LLC grew its position in shares of Nektar Therapeutics by 0.6% in the 1st quarter. Vident Investment Advisory LLC now owns 100,706 shares of the biopharmaceutical company’s stock valued at $2,015,000 after buying an additional 632 shares during the last quarter. Nordea Investment Management AB grew its position in shares of Nektar Therapeutics by 2.2% in the 1st quarter. Nordea Investment Management AB now owns 31,865 shares of the biopharmaceutical company’s stock valued at $633,000 after buying an additional 685 shares during the last quarter. Grandfield & Dodd LLC grew its position in shares of Nektar Therapeutics by 3.1% in the 2nd quarter. Grandfield & Dodd LLC now owns 28,058 shares of the biopharmaceutical company’s stock valued at $480,000 after buying an additional 850 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in shares of Nektar Therapeutics by 1.5% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 60,777 shares of the biopharmaceutical company’s stock valued at $1,216,000 after buying an additional 869 shares during the last quarter. Finally, US Bancorp DE grew its position in shares of Nektar Therapeutics by 0.4% in the 2nd quarter. US Bancorp DE now owns 270,263 shares of the biopharmaceutical company’s stock valued at $4,638,000 after buying an additional 969 shares during the last quarter. Hedge funds and other institutional investors own 90.59% of the company’s stock.

A number of equities research analysts have commented on the company. Stifel Nicolaus upgraded Nektar Therapeutics from a “hold” rating to a “buy” rating and upped their price target for the company from $22.00 to $24.00 in a research report on Monday, June 28th. Bank of America initiated coverage on Nektar Therapeutics in a research note on Friday, September 10th. They issued a “neutral” rating and a $18.00 price objective on the stock. SVB Leerink dropped their price objective on Nektar Therapeutics from $20.00 to $19.00 and set a “market perform” rating on the stock in a research note on Friday, August 6th. Finally, Zacks Investment Research raised Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 price objective on the stock in a research note on Wednesday, August 4th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Nektar Therapeutics currently has an average rating of “Buy” and a consensus target price of $20.80.

In related news, Director Myriam Curet sold 3,665 shares of the company’s stock in a transaction that occurred on Wednesday, September 22nd. The stock was sold at an average price of $17.78, for a total transaction of $65,163.70. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Mark Andrew Wilson sold 1,910 shares of the company’s stock in a transaction that occurred on Monday, August 16th. The stock was sold at an average price of $13.83, for a total value of $26,415.30. Following the transaction, the senior vice president now directly owns 200,915 shares in the company, valued at $2,778,654.45. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 57,482 shares of company stock worth $837,314. 2.91% of the stock is owned by company insiders.

Shares of NASDAQ:NKTR opened at $17.07 on Thursday. The business’s 50-day moving average is $16.02 and its 200-day moving average is $17.30. Nektar Therapeutics has a 1 year low of $12.92 and a 1 year high of $26.75. The company has a market capitalization of $3.14 billion, a price-to-earnings ratio of -6.49 and a beta of 1.46.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Thursday, August 5th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.03. Nektar Therapeutics had a negative return on equity of 45.74% and a negative net margin of 449.67%. The business had revenue of $28.33 million for the quarter, compared to the consensus estimate of $26.42 million. Research analysts predict that Nektar Therapeutics will post -3.02 EPS for the current fiscal year.

About Nektar Therapeutics

Nektar Therapeutics is a research-based biopharmaceutical company that focuses on discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and auto-immune disease.

Featured Article: Trading Strategy Examples and Plans

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.